Although pevonedistat has been tested in MPM in the context of NF2 loss and now is being tested in clinical trials for MPM, there has not been a mechanistic detail explaining the treatment efficacy in vivo and possible effects on the tumor microenvironment. This evidence concerns the gene NF2 and neoplasm.